|The AZBio Expo is the place where you can connect with Arizona’s growing bioscience community to engage, collaborate, and move your bioscience business…. Forward Faster.
Showcase your products and services…
Show off your Expertise…
Find Partners and Resources.
Registration for the Event is CLOSED as of 1:30 pm on Wednesday, July 18th. On-Site registrations are welcome. If you wish to attend please show up and ask to see Megan Pratt at the registration desk. Looking forward to seeing everyone tomorrow!
Join us June 19, 2014 at the Scottsdale Conference Center and Resort as we look at bringing bioscience to life and learn the latest updates from Arizona’s Bioscience Companies and Life Science Leaders as we explore…
New Frontiers in Health
9:00 AM – Registration and Exhibit Floor Opens
- Continental Breakfast Available in the Exhibit Hall
10:00 AM – Opening General Session *
Welcome by Mayor Jim Lane, City of Scottsdale, Arizona
Mayor W. J. “Jim” Lane served for four years on the Scottsdale City Council beginning in June 2004, and began his first term as Mayor in January 2009. He was re-elected to the Mayor’s Office in 2012 and began his second term in January of 2013.
Mayor Lane serves as a member of the Arizona Bioscience Roadmap Steering Committee and has been a lead driver in the development of Scottsdale’s Cure Corridor.
Panel Discussion: Funding Pathways for Innovators
Moderated by Joan Koerber-Walker
Kelly Slone, Vice President, Life Science Policy at the National Venture Capital Association
Kelly Slone serves as Vice President, Life Science Policy at the National Venture Capital Association (NVCA) NVCA is the national trade association for the venture capital industry; its mission is to foster understanding of the importance of venture capital to the vitality of the U.S. and global economies.
Slone is responsible for raising the visibility of NVCA’s life science members to congressional, administrative, and regulatory leaders with regard to the important role venture capital plays in the creation and development of disruptive medical therapies and technologies. She is also the lead lobbyist on public policy issues that affect life science investors and their portfolio companies, including healthcare reform, FDA reform, CMS reimbursement, patent reform, and small-business issues such as those related to SBA’s SBIR grant program. She also partners with other health-related trade associations and patient advocacy groups to coordinate and leverage key policies and messages important to the advancement of U.S. medical innovation.In 2010, Slone directed the launch of NVCA’s Medical Innovation and Competitiveness Coalition (MedIC), a coalition of the top U.S. venture capital firms, their portfolio companies, and entrepreneurs dedicated to developing policies to advance U.S. leadership in medical innovation. She is a member of MedIC’s steering committee, and also represents NVCA as a partner of the Council for American Medical Innovation (CAMI).
Prior to joining NVCA, Slone spent 11 years as senior director of legislative and international trade affairs for Baxter Health Corp., a Fortune 50 healthcare company. In this capacity she lobbied, developed, and implemented strategies on a wide range of issues, including FDA reform, the development of FDA user fees, product liability, and various corporate tax issues. She also managed the company’s political action committee.
MaryAnn Guerra, BioAccel
MaryAnn Guerra is currently Chairman of the Board, Chief Executive Officer, and co-founder of BioAccel™. Ms. Guerra is well known for creating novel programs to accelerate the transfer of technology from the lab into useful products and new business opportunities. Ms. Guerra has spent her career operating successful and progressive health, science and technology businesses. She is an expert at business development and strategic planning initiatives that create organizations poised to deliver commercial outcomes. Since the launch of BioAccel in April 2009, 10 companies have been successfully launched with products close to commercial availability. Additional new technologies and companies are under development. Additionally BioAccel partnered with the City of Peoria to create the first medical device accelerator, embedding the BioAccel philanthrocapitalism model into its operations. In May 2013 BioAccel received the City of Peoria’s, City Manager’s Award for Outstanding Partnership in Economic Development. Prior to founding BioAccel, Ms. Guerra served as President of TGen Accelerators, LLC and Chief Operating Officer at the Translational Genomics Research Institute (TGen). While at TGen she facilitated the start-up of 6 companies and was involved in the sale of 3 of those that yielded significant profits for the organization. As TGen’s former COO she grew the organization from $30M to over $60M in less than 3 years.
Paul Jackson, Worthworm and Integrus Capital
Paul Jackson is an entrepreneur, angel investor, and aerospace engineer. His engineering expertise and entrepreneurial spirit are driving forces behind his founding of Integrus Capital, and co-founding its flagship offerings, Worthworm and D-Strut LLC. After a successful career as a dynamics engineer for Orbital Sciences and a commercial space development consultant in Washington D.C., Mr. Jackson founded Dynamic Labs, a recognized leader in environmental testing dedicated to testing and evaluating products in the early stages of development for commercial and military applications. Dynamic Labs served approximately 80% of the high-tech industry in the American Southwest, including defense primes such as Boeing, Lockheed, Raytheon and Honeywell.
After selling Dynamic Labs to a publicly held company in 2006, Paul has applied his engineering skills to the development of risk-analysis products that contribute to the larger vision of re-purposing under-commercialized intellectual property found at Fortune 100 companies. His interest in finding a scalable solution for knowhow left languishing at his established aerospace customer base has driven the development of new technologies, such as those utilized in Worthworm. His understanding of emergent systems, real-options analysis, and state-of-the-art business analytics techniques is driving future Integrus Capital products designed for example, to match and map IP with markets or assist with capital allocation decisions across a portfolio of investment opportunities.
Advancing Innovation Through Public-Private Partnerships
Martha Brumfield, PhD – President & CEO
The Critical Path Institute
Public Private Partnerships were envisioned by the FDA 10 years ago in their report “Stagnation and Innovation” and C-Path is one of the few organizations that has successfully implemented parts of this vision. The uniqueness of being a “neutral, third-party” enticed competitive biopharmaceutical companies to join together in sharing expertise and actual data toward the greater benefit for advancing techniques to develop medicines faster and get them to the patients who are waiting. FDA, EMA and PMDA have collaborated in each of C-Path’s 7 global consortia in offering advice toward a formal regulatory acceptance of new tools and methods. The presentation will review successes from two of these consortia which are focused on developing biomarkers and modeling and simulation tools to expedite new treatments for Alzheimer’s disease and Polycystic Kidney disease
Robert Penny, MD, PhD, - Founder and CEO
Paradigm and International Genomics Consortium (IGC)
Dr. Robert Penny is Founder and CEO of Paradigm, a cutting-edge advanced diagnostics company that will help usher in the age of personalized medicine. Dr. Penny drove the vision and launch of the company, along with Dr. Jay Hess to provide improved cancer treatments based on an individual’s cancer’s unique biology. This is his sixth start up company; the previous five are all successful in the practice of medicine and financially.
11:30 AM – Networking Break in the Exhibit Hall *
12:00 PM – Luncheon Keynote
New Frontiers in Health
Vice President & General Manager, Medtronic Tempe Campus
Ron Wilson is the Vice President and General Manager of the Medtronic Tempe Campus (MTC) in Tempe, Arizona. Ron has been in his current position since June 28, 2013. Prior to this promotion, he served as General Manager and Site Leader.
Ron began his career at Medtronic in June, 1986 out of Northern Arizona University, where he earned his Bachelors degree in Electrical Engineering. During his tenure at Medtronic, Ron has held positions of increasing leadership in Product Engineering, Product Development and Process Engineering. As Sr Director, he was responsible for New Product Development and Released Product Engineering, covering Product performance from concept through end of service.
Medtronic career highlights include engineering and product management contributions on a long line of successful Medtronic product development projects, leading MTC’s wafer fab through its outsourcing transition to ST Microelectronics and most recently leading product engineering functions in support of the Medtronic Tempe Campus Strategic Agenda.
Ron is a native of Arizona, and currently lives in central Phoenix with his wife Mary, and three daughters.
1:30 PM – Networking Break in the Exhibit Hall *
2:00 PM – General Session 2
Polio, or poliomyelitis, is an infectious viral disease that can strike at any age and affects a person’s nervous system. In the late 1940s to the early 1950s, polio crippled an average of more than 35,000 people in the United States each year; it was one of the most feared diseases of the twentieth century. Thanks to the polio vaccine, dedicated health care professionals, and parents who vaccinate their children on schedule, polio has been eliminated in this country for more than 30 years. (Source: CDC) Today the US is home to approximately 1 million polio survivors. Join our panelists in a look at what polio was, the impacts polio has on Americans today, and the importance of vaccinations in our ever shrinking world.
Moderator: Gapar Laca, State Government Affairs Director at GlaxoSmithKline
Panelists: David Larwood, CEO, President – Valley Fever Solutions, Debbie McCune Davis, Executive Director, The Arizona Partnership for Immunization (TAPI)
WhiteSpace Enterprise Corporation
Frederic Zenhausern, Ph.D., MBA, President
WhiteSpace Enterprise Corporation (“WSE”) is developing platform technologies and commercial products combining methods from physical sciences and integrated microsystems for automating and miniaturizing the workflow processing of biological specimens. These platforms have broad applications for point-of-care testing that will enable precise and mobile health analysis ranging from rapid DNA analysis to predictive biomarkers for molecular diagnostics. The company’s design of genomic and proteomic biomarkers panel for monitoring radiation sensitivities will provide new ways for guiding personalized treatment in radiotherapies that that will improve value in healthcare delivery.
Kalos Therapeutics, Inc.
Michael Kozlowski OD, PHD, Chief Science Officer
Kalos Therapeutics, Inc dedicated to treating patients not just their diseases. Kalos is a peptide therapeutic company treating virulent cancers and the related comorbidities. The Kalos solution focuses in putting tumor cells into a prolonged non dividing state, also treating the ascites and edema that lead to pain and death. Kalos drugs engage known pathway receptors in the MAPK pathway and it does so more efficiently without the side effects associated with chemotherapeutic compounds. As confirmed in an Investigator IND our clinical effects of increased natriuresis and diuresis will treat the related comorbidities of cancer reducing ascites, and edema, as well as shrinking the tumor.
Bharath Takulapalli, Founder & CEO
INanoBio is developing advanced nano sensor technologies for ultra-fast Genome Sequencing & Personalized Diagnostics. With our unique capability combining both nanotechnology and biomedicine, we aim to develop high-impact solutions for personalized healthcare of the future.
Valley Fever Solutions
David Larwood, CEO
Valley Fever Solutions is preparing to start Phase IIa trials on a drug candidate that is a new class of antifungal, specifically for Valley Fever, an orphan indication. We are looking at improved diagnostics for the disease, and collaborate closely with a group that is also studying vaccine candidates.
Reaching Your Destination – An Arizona Success Story
Darryl Baker, Chief Financial Officer
of Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company based in Chandler, Arizona that develops and commercializes innovative supportive care products. In one of the hottest years for biotech IPO’s in recent memory, Insys was the top performing IPO of 2013 with over 380% growth in shareholder value and a market cap in excess of $800 million at the end of the year.
Join us as Darryl Baker, Chief Financial Officer of Insys, shares insights from their journey and takes a look at the road ahead.
Learn more about Darryl.
4:00 PM – Expo Concludes
*Note: The Exhibit Halls will be closed during the General Sessions and reopened again during the Breaks.
Join us after the Expo for Cocktails at Sangria’s Lounge from 4 – 6 PM
At the end of the day, connect with old friends and new connections at Sangria’s Lounge (just off the resort’s Main Lobby.
Catch all of the sports of the day on Sangria’s plasma TV screens.
The billiards room, with four antique billiards tables, is flanked by a wall of French doors that open to shady patios bordering on the neighboring golf courses.
What a great way to end the day!
Early Bird Rates – End April 30, 2013
AZBio Members ($150) Guests ($225), Full Time Students ($75)
Regular Rate – After April 30th
AZBio Members ($200), Guests ($300), Full Time Students ($100)
Student Discovery Posters:
Student Posters: Complimentary Admission and Display
(Poster must be approved by review committee – Contributor must be a full time student)
Showcase your bioscience achievements and services
8 ×10 Exhibit Booth and Half Page Ad
Early Bird Rates – End April 30, 2013
AZBio Members ($1,500), Guests ($2,250)
Regular Rate – After April 30th
AZBio Members ($2,000), Guests ($3000)
Contact Our Member Support Team